• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一系列异基因外周血干细胞移植受者病例中,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)持续传染性超过50天。

Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients.

作者信息

Han Alice, Rodriguez Tulio E, Beck Eric T, Relich Ryan F, Udeoji Dioma U, Petrak Robert, Chundi Vishnu V

机构信息

Metro Infectious Disease Consultants, 901 McClintock Drive, Suite 201, Burr Ridge, Chicago, IL 60527, United States.

Department of Medicine, Advocate Lutheran General Hospital, Advocate Aurora Health, Rosalind Franklin University of Medicine and Science, North Chicago, United States.

出版信息

Curr Probl Cancer Case Rep. 2021 Mar;3:100057. doi: 10.1016/j.cpccr.2021.100057. Epub 2021 Jan 16.

DOI:10.1016/j.cpccr.2021.100057
PMID:34308401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7834336/
Abstract

The coronavirus disease 19 (COVID-19) pandemic has infected tens of millions across the world, but there is a significant gap in our understanding about COVID-19 in the hematopoietic stem transplant (HSCT) recipient population. Prolonged viral shedding is frequently observed with severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), but studies suggest viral loads decline 10 days after symptom onset. Current CDC guidance suggests that severely ill and immunocompromised hosts are no longer infectious after 20 days from symptom onset. Cycle threshold (Ct) values are inversely proportional to the viral load and are used to detect SARS-CoV-2 RNA concentration. Specimens with reverse transcriptase PCR (RT-PCR) Ct values > 33-34 have been associated with inability to culture virus, and have been used as a surrogate for diminished infectivity. We report two cases of  allogeneic peripheral blood stem cell transplant (PBSCT) recipients who had prolonged durations of infectivity with SARSCov-2, based on culture positivity and persistently low Ct values for greater than 50 days.

摘要

新型冠状病毒肺炎(COVID-19)大流行已在全球感染了数千万人,但我们对造血干细胞移植(HSCT)受者群体中COVID-19的了解存在重大差距。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)经常出现病毒长时间脱落的情况,但研究表明,症状出现10天后病毒载量会下降。美国疾病控制与预防中心(CDC)目前的指导意见表明,重症和免疫功能低下的宿主在症状出现20天后不再具有传染性。循环阈值(Ct)值与病毒载量成反比,用于检测SARS-CoV-2 RNA浓度。逆转录聚合酶链反应(RT-PCR)Ct值>33-34的样本与无法培养出病毒有关,并已被用作传染性降低的替代指标。我们报告了两例异基因外周血干细胞移植(PBSCT)受者,基于培养阳性和持续50多天的低Ct值,他们感染SARS-CoV-2的时间延长。

相似文献

1
Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients.在一系列异基因外周血干细胞移植受者病例中,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)持续传染性超过50天。
Curr Probl Cancer Case Rep. 2021 Mar;3:100057. doi: 10.1016/j.cpccr.2021.100057. Epub 2021 Jan 16.
2
Viral cultures, cycle threshold values and viral load estimation for assessing SARS-CoV-2 infectiousness in haematopoietic stem cell and solid organ transplant patients: a systematic review.用于评估造血干细胞和实体器官移植患者中SARS-CoV-2传染性的病毒培养、循环阈值和病毒载量估计:一项系统综述
J Hosp Infect. 2023 Feb;132:62-72. doi: 10.1016/j.jhin.2022.11.018. Epub 2022 Dec 5.
3
Isolation of SARS-CoV-2 in Viral Cell Culture in Immunocompromised Patients With Persistently Positive RT-PCR Results.免疫功能低下的持续性 RT-PCR 阳性结果患者的病毒细胞培养中 SARS-CoV-2 的分离。
Front Cell Infect Microbiol. 2022 Feb 2;12:804175. doi: 10.3389/fcimb.2022.804175. eCollection 2022.
4
SARS-CoV-2 viral load dynamics and real-time RT-PCR cycle threshold interpretation in symptomatic non-hospitalised individuals in New Zealand: a multicentre cross sectional observational study.新西兰有症状非住院个体中SARS-CoV-2病毒载量动态及实时逆转录聚合酶链反应循环阈值解读:一项多中心横断面观察性研究
Pathology. 2021 Jun;53(4):530-535. doi: 10.1016/j.pathol.2021.01.007. Epub 2021 Mar 20.
5
Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples.从诊断样本中预测传染性严重急性呼吸综合征冠状病毒 2。
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666. doi: 10.1093/cid/ciaa638.
6
Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia.病例报告:SARS-CoV-2 阳性受者异基因造血干细胞移植的良好结局,感染与白血病之间的风险效益平衡。
Front Immunol. 2023 May 23;14:1184956. doi: 10.3389/fimmu.2023.1184956. eCollection 2023.
7
Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.《COVID-19 中的每日病毒动力学和固有及适应性免疫反应评估:病例系列》。
mSphere. 2020 Nov 11;5(6):e00827-20. doi: 10.1128/mSphere.00827-20.
8
Viral Cultures for Coronavirus Disease 2019 Infectivity Assessment: A Systematic Review.评估 2019 年冠状病毒病传染性的病毒培养:系统评价。
Clin Infect Dis. 2021 Dec 6;73(11):e3884-e3899. doi: 10.1093/cid/ciaa1764.
9
Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study.非危重新冠肺炎患者中可检测到的存活 SARS-CoV-2、总 SARS-CoV-2 RNA 和亚基因组 SARS-CoV-2 RNA 的持续时间:一项前瞻性队列研究。
Microbiol Spectr. 2022 Jun 29;10(3):e0050322. doi: 10.1128/spectrum.00503-22. Epub 2022 May 23.
10
An approach to lifting self-isolation for health care workers with prolonged shedding of SARS-CoV-2 RNA.解除对 SARS-CoV-2 RNA 持续排出的医护人员的自我隔离的方法。
Infection. 2021 Feb;49(1):95-101. doi: 10.1007/s15010-020-01530-4. Epub 2020 Oct 6.

引用本文的文献

1
Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID-19 infection at an ambulatory cancer center.在一家癌症门诊中心,接受 bebtelovimab 治疗 COVID-19 感染的免疫抑制患者的临床结局和持续感染发生率。
Transpl Infect Dis. 2024 Feb;26(1):e14223. doi: 10.1111/tid.14223. Epub 2024 Jan 8.
2
Coronavirus Disease-2019 in the Immunocompromised Host.新型冠状病毒病在免疫功能低下宿主中的研究进展
Clin Chest Med. 2023 Jun;44(2):395-406. doi: 10.1016/j.ccm.2022.11.012. Epub 2022 Nov 22.
3
Viral cultures, cycle threshold values and viral load estimation for assessing SARS-CoV-2 infectiousness in haematopoietic stem cell and solid organ transplant patients: a systematic review.用于评估造血干细胞和实体器官移植患者中SARS-CoV-2传染性的病毒培养、循环阈值和病毒载量估计:一项系统综述
J Hosp Infect. 2023 Feb;132:62-72. doi: 10.1016/j.jhin.2022.11.018. Epub 2022 Dec 5.
4
Successful treatment of proven coronavirus disease 2019-associated pulmonary aspergillosis with liposomal amphotericin B in a patient with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后闭塞性细支气管炎综合征患者合并新型冠状病毒病 2019 相关肺曲霉病,使用脂质体两性霉素 B 成功治疗。
J Infect Chemother. 2023 Feb;29(2):223-227. doi: 10.1016/j.jiac.2022.10.020. Epub 2022 Nov 13.
5
Correlation between Type I Interferon Associated Factors and COVID-19 Severity.I 型干扰素相关因素与 COVID-19 严重程度的相关性。
Int J Mol Sci. 2022 Sep 19;23(18):10968. doi: 10.3390/ijms231810968.
6
Intra-host evolution during SARS-CoV-2 prolonged infection.SARS-CoV-2长期感染期间的宿主体内进化。
Virus Evol. 2021 Sep 29;7(2):veab078. doi: 10.1093/ve/veab078.

本文引用的文献

1
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).COVID-19 住院患者中感染性病毒排出的持续时间和关键决定因素。
Nat Commun. 2021 Jan 11;12(1):267. doi: 10.1038/s41467-020-20568-4.
2
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer.癌症免疫抑制治疗后活的严重急性呼吸综合征冠状病毒2的脱落
N Engl J Med. 2020 Dec 24;383(26):2586-2588. doi: 10.1056/NEJMc2031670. Epub 2020 Dec 1.
3
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.恢复期血浆治疗重症 COVID-19:一项倾向评分匹配对照研究。
Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.
4
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.瑞德西韦对比标准治疗对 11 天内中症 COVID-19 患者临床状态的影响:一项随机临床试验。
JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349.
5
Convalescent Plasma Therapy for COVID-19: State of the Art.恢复期血浆疗法治疗 COVID-19:最新进展。
Clin Microbiol Rev. 2020 Aug 12;33(4). doi: 10.1128/CMR.00072-20. Print 2020 Sep 16.
6
Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients.造血细胞移植和细胞治疗受者 COVID-19 管理指南。
Biol Blood Marrow Transplant. 2020 Nov;26(11):1983-1994. doi: 10.1016/j.bbmt.2020.07.027. Epub 2020 Jul 28.
7
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
8
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
9
Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19.基于培养的病毒分离法评估用于检测 COVID-19 的临床标本的潜在传染性。
J Clin Microbiol. 2020 Jul 23;58(8). doi: 10.1128/JCM.01068-20.
10
Comparison of Two Commercial Molecular Tests and a Laboratory-Developed Modification of the CDC 2019-nCoV Reverse Transcriptase PCR Assay for the Detection of SARS-CoV-2.两种商业分子检测方法与一种实验室开发的对疾病控制与预防中心(CDC)2019新型冠状病毒逆转录聚合酶链反应(PCR)检测法的改良方法用于检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的比较
J Clin Microbiol. 2020 Jul 23;58(8). doi: 10.1128/JCM.00938-20.